Anticoagulant effects of Edoxiaban and those inhibitors in patients with venous thromboembolism.

Anticoagulant effects of Edoxiaban and those inhibitors in cancer and non-cancer patients with venous thromboembolism. - EVE study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041973

Enrollment

800

Registered

2020-10-05

Start date

2020-10-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous thromboembolism (VTE)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients taking Edoxaban after VTE diagnosis.

Exclusion criteria

Exclusion criteria: Patients under 20 years-old. Patients with hemodynamically insufficiency. Patients who need thrombolytic therapy or emergent thrombectomy. Terminal cancer patients those life prognosis are less than 3 months. Patients taking Edoxaban, unfractionated heparin or fondaparinux before VTE diagnosis.

Design outcomes

Primary

Measure	Time frame
PT, APTT and D-dimer value after Edoxaban administration.	—

Secondary

Measure	Time frame
Compare delta PT and delta APTT (difference in PT or APTT value before and 5 hours after Edoxaban administration) in cancer and non-cancer patients. Identify the time when D-dimer decrease below 50% of baseline value. Compare changes of D-dimer value after Edoxaban administration in cancer and non-cancer patients. Identify factors those inhibit PT and APTT prolongation by Edoxaban administration. Identify factors those inhibit D-dimer decrease by Edoxaban administration. Assess recurrent VTE, interruption of Edoxaban administration, major bleeding events, clinically relevant non-major bleeding events and death.	—

Measure

Time frame

Compare delta PT and delta APTT (difference in PT or APTT value before and 5 hours after Edoxaban administration) in cancer and non-cancer patients. Identify the time when D-dimer decrease below 50% of baseline value. Compare changes of D-dimer value after Edoxaban administration in cancer and non-cancer patients. Identify factors those inhibit PT and APTT prolongation by Edoxaban administration. Identify factors those inhibit D-dimer decrease by Edoxaban administration. Assess recurrent VTE, interruption of Edoxaban administration, major bleeding events, clinically relevant non-major bleeding events and death.

—

Countries

Japan

Contacts

Public ContactMasashi Yoshida

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science Department of CKD and CVD

yoshid-m@cc.okayama-u.ac.jp0862357351

Outcome results